Mayo Clinic challenged its own nurses to pitch autonomous AI agent ideas, drawing more than 450 entries and 33 finalists now building prototypes with Microsoft, with the full nursing department set to vote on which ones move forward.
St. Luke's Health System has selected hellocare.ai to deploy AI-assisted virtual nursing, virtual sitting and connected-room technology across its southern Idaho hospitals, part of a fast-growing national push into enterprise virtual care.
Character.AI and Google settled five lawsuits alleging the company's chatbot companions contributed to teen suicides and severe mental health harm, even as a broader wave of similar litigation against AI chatbot makers continues to grow.
Nanowear's SimpleSense-Wrist patch won FDA Breakthrough Device Designation for non-invasive vascular monitoring, extending the company's fabric-sensor wearable platform into a technically challenging new cardiovascular category.
Abbott won FDA clearance for the first wearable that continuously tracks both glucose and ketones, a combination clinicians say could help catch dangerous ketoacidosis earlier in diabetes patients taking SGLT2 inhibitor medications.
HIMSS's AI Executive Leadership Summit and AI in Healthcare Forum brought hospital leaders to San Diego to confront a widening gap between fast-moving AI adoption and the governance infrastructure needed to deploy it safely.
The American Hospital Association pushed back on insurer accusations that hospitals use AI to inflate billing codes, framing the dispute as part of a broader arms race in which both payers and providers deploy AI in claims processing.
Major medical societies pushed back on growing AI autonomy in clinical care, arguing diagnostic AI remains a valuable tool but physician judgment must stay central, especially for cases falling outside a model's training patterns.
Twelve US health systems formed a collaborative to jointly validate diagnostic AI tools across a broader, more diverse patient population, aiming to close the gap between AI performance in controlled studies and real-world hospital use.
Researchers unveiled an AI tool at EASD 2026 that flags signs of type 2 diabetes from just 20 seconds of speech, an early-stage finding that could eventually enable low-cost screening but still requires much larger validation studies.